From Wikipedia, the free encyclopedia
  (Redirected from GEMOX)
Jump to navigation Jump to search

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma.

When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.

The [R]-GemOx regimen consists of:

  1. (R)ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
  2. (Gem)citabine - an antimetabolite;
  3. (Ox)aliplatin - a platinum-based alkylating antineoplastic agent.[1][2]

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(Gem)citabine 1000 mg/m2 IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min Day 2
(Ox)aliplatin 100 mg/m2 IV infusion over 2hrs Day 2